Icatibant Drug Discount Agreement
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Icatibant (ATC-Code nach WHO: B06AC02)
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No guaranteed minimum purchase quantities; actual demand depends on prescribing behavior and patient numbers.
The buyer reserves the right to terminate the open-house procedure early if exclusive agreements are concluded, which t...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- May 31, 2028
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2028
- Conclusion of non-exclusive discount agreements for Icatibant (ATC B06AC02)
- Supply of pharmaceutical products to the AOK PLUS health insurance for patients in Saxony and Thuringia
Show full summary
Non-exclusive drug discount agreement for Icatibant under the Open-House model. Any interested pharmaceutical company can participate. No guaranteed volumes, no exclusive rights. The contract ends at the latest on 31 May 2028. The procedure is published for transparency but is not a public procurement subject to EU directives.
Risks
No guaranteed minimum purchase quantities; actual demand depends on prescribing behavior and patient numbers.
The buyer reserves the right to terminate the open-house procedure early if exclusive agreements are concluded, which t...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Participant must be a pharmaceutical undertaking as defined in § 4 Abs. 18 AMG
Eligibility
- Must submit declaration of no exclusion grounds per §§ 123, 124 GWB
Administrative
- Must submit declaration regarding Russia sanctions (EU Regulation 833/2014)
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Icatibant Drug Discount Agreement
Non-exclusive discount agreement for pharmaceuticals containing Icatibant (ATC B06AC02). Open to all qualified pharmaceutical undertakings. No minimum purchase quantities. Contract ends 31 May 2028. The agreement may be terminated earlier if exclusive agreements are concluded.
Location
Duration
Category
Award Criteria
Deadline
Award details
No award criteria
participation is open to all who meet the requirements and accept the terms.
Value note
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Icatibant (ATC-Code nach WHO: B06AC02)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 12 Mar 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 174735-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No guaranteed minimum purchase quantities; actual demand depends on prescribing behavior and patient numbers.
The buyer reserves the right to terminate the open-house procedure early if exclusive agreements are concluded, which t...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications